Savara Inc (NASDAQ:SVRA) Holdings Boosted by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. grew its holdings in Savara Inc (NASDAQ:SVRA) by 54.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 690,609 shares of the company’s stock after purchasing an additional 242,249 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Savara were worth $2,928,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Jennison Associates LLC raised its position in Savara by 17.5% during the third quarter. Jennison Associates LLC now owns 6,732,776 shares of the company’s stock valued at $28,547,000 after buying an additional 1,001,296 shares during the period. LMR Partners LLP grew its stake in Savara by 138.3% during the 3rd quarter. LMR Partners LLP now owns 36,800 shares of the company’s stock valued at $156,000 after acquiring an additional 132,900 shares in the last quarter. Oppenheimer & Co. Inc. grew its stake in Savara by 14.8% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 115,604 shares of the company’s stock valued at $490,000 after acquiring an additional 14,867 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Savara by 7.0% in the 3rd quarter. Victory Capital Management Inc. now owns 140,010 shares of the company’s stock valued at $594,000 after purchasing an additional 9,180 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Savara by 95.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 31,658 shares of the company’s stock worth $134,000 after purchasing an additional 15,423 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Price Performance

Shares of SVRA opened at $3.36 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The firm has a market cap of $576.64 million, a PE ratio of -7.81 and a beta of 1.02. Savara Inc has a twelve month low of $2.82 and a twelve month high of $5.70. The firm’s 50 day moving average price is $3.76 and its 200 day moving average price is $4.12.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11). As a group, research analysts expect that Savara Inc will post -0.45 EPS for the current fiscal year.

Insider Buying and Selling at Savara

In related news, Director Joseph S. Mccracken bought 20,000 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average price of $2.95 per share, with a total value of $59,000.00. Following the completion of the transaction, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.13% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on SVRA. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 price objective (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. JMP Securities reissued a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st. Finally, HC Wainwright dropped their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $10.17.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.